Patents by Inventor Joshua A. Kaplan

Joshua A. Kaplan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • FXR (NR1H4) MODULATING COMPOUNDS
    Publication number: 20250026744
    Abstract: The present disclosure relates generally to compounds that bind to FXR and act as agonists of FXR. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.
    Type: Application
    Filed: June 18, 2024
    Publication date: January 23, 2025
    Inventors: Peter A. Blomgren, Kevin S. Currie, Morin Mae Frick, Elizabeth M. Horstman, Joshua A. Kaplan, Jeffrey E. Kropf, William J. Watkins
  • SULFINYLAMINOBENZAMIDE AND SULFONYLAMINOBENZAMIDE DERIVATIVES
    Publication number: 20240409508
    Abstract: Provided is a compound of Formula (I): wherein the variable groups are defined herein.
    Type: Application
    Filed: June 13, 2024
    Publication date: December 12, 2024
    Inventors: Julie FARAND, Joshua A. KAPLAN, Gregory NOTTE, Casey Lockwood OLEN, Michael SANGI, David SPERANDIO
  • Substituted pyrrolizine compounds and uses thereof
    Patent number: 12161625
    Abstract: This application relates generally to certain substituted pyrrolizine compounds, and pharmaceutical compositions which inhibit HBV replication, and methods of making and using them.
    Type: Grant
    Filed: November 29, 2022
    Date of Patent: December 10, 2024
    Assignee: Gilead Sciences, Inc.
    Inventors: Jinfa Du, Joshua A. Kaplan, Thorsten A. Kirschberg, Tetsuya Kobayashi, Scott E. Lazerwith, Rick Andrew Lee, Jonathan William Medley, Michael L. Mitchell, Philip Anthony Morganelli, Hyung-Jung Pyun, Sophia L. Shevick, Neil H. Squires, William J. Watkins
  • Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives
    Patent number: 12049439
    Abstract: Provided is a compound of Formula (I): wherein the variable groups are defined herein.
    Type: Grant
    Filed: August 31, 2021
    Date of Patent: July 30, 2024
    Assignee: OrsoBio, Inc.
    Inventors: Julie Farand, Joshua A. Kaplan, Gregory Notte, Casey Lockwood Olen, Michael Sangi, David Sperandio
  • LPA receptor antagonists and uses thereof
    Patent number: 11980609
    Abstract: The present disclosure relates generally to compounds that bind to Lysophosphatidic Acid Receptor 1 (LPAR1) and act as antagonists of LPAR1. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of LPAR1, including fibrosis and liver diseases such as non-alcoholic steatohepatitis (NASH), interstitial lung disease (TLD), or chronic kidney disease (CKD).
    Type: Grant
    Filed: May 10, 2022
    Date of Patent: May 14, 2024
    Assignee: Gilead Sciences, Inc.
    Inventors: Brian P. Bestvater, Joshua A. Kaplan, Megan E. Neubig, Kin S. Yang, Anna Zagorska
  • LPA receptor antagonists and uses thereof
    Patent number: 11939318
    Abstract: The present disclosure relates generally to compounds that bind to Lysophosphatidic Acid Receptor 1 (LPAR1) and act as antagonists of LPAR1. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of LPAR1, including fibrosis and liver diseases such as non-alcoholic steatohepatitis (NASH), interstitial lung disease (ILD), or chronic kidney disease (CKD).
    Type: Grant
    Filed: December 6, 2022
    Date of Patent: March 26, 2024
    Assignee: Gilead Sciences, Inc.
    Inventors: Brian P. Bestvater, Joshua A. Kaplan, Barton W. Phillips, Kin S. Yang, Anna Zagorska
  • SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF
    Publication number: 20230270719
    Abstract: This application relates generally to certain substituted pyrrolizine compounds, and pharmaceutical compositions which inhibit HBV replication, and methods of making and using them.
    Type: Application
    Filed: November 29, 2022
    Publication date: August 31, 2023
    Inventors: Jinfa Du, Joshua A. Kaplan, Thorsten A. Kirschberg, Tetsuya Kobayashi, Scott E. Lazerwith, Rick Andrew Lee, Jonathan William Medley, Michael L. Mitchell, Philip Anthony Morganelli, Hyung-Jung Pyun, Sophia L. Shevick, Neil H. Squires, William J. Watkins
  • LPA RECEPTOR ANTAGONISTS AND USES THEREOF
    Publication number: 20230212151
    Abstract: The present disclosure relates generally to compounds that bind to Lysophosphatidic Acid Receptor 1 (LPAR1) and act as antagonists of LPAR1. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of LPAR1, including fibrosis and liver diseases such as non-alcoholic steatohepatitis (NASH), interstitial lung disease (ILD), or chronic kidney disease (CKD).
    Type: Application
    Filed: December 6, 2022
    Publication date: July 6, 2023
    Inventors: Brian P. Bestvater, Zhimin Du, Julie Farand, Joshua A. Kaplan, Barton W. Phillips, Doris T. Tang, Chandrasekar Venkataramani, Peiyuan Wang, Kin S. Yang, Anna Zagorska
  • LPA RECEPTOR ANTAGONISTS AND USES THEREOF
    Publication number: 20230212150
    Abstract: The present disclosure relates generally to compounds that bind to Lysophosphatidic Acid Receptor 1 (LPAR1) and act as antagonists of LPAR1. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of LPAR1, including fibrosis and liver diseases such as non-alcoholic steatohepatitis (NASH), interstitial lung disease (ILD), or chronic kidney disease (CKD).
    Type: Application
    Filed: December 6, 2022
    Publication date: July 6, 2023
    Inventors: Brian P. Bestvater, Joshua A. Kaplan, Barton W. Phillips, Kin S. Yang, Anna Zagorska
  • KHK INHIBITORS
    Publication number: 20230079863
    Abstract: Compounds of formula: wherein the variable substituents are defined herein.
    Type: Application
    Filed: March 25, 2022
    Publication date: March 16, 2023
    Inventors: James L. Bachman, Daniel H. Byun, Christopher T. Clark, Petr Jansa, Joshua A. Kaplan, Zachary A. Kasun, Jennifer R. Lo, Megan E. Neubig, Nathaniel H. Stanley, Kirk L. Stevens
  • LPA receptor antagonists and uses thereof
    Patent number: 11584738
    Abstract: The present disclosure relates generally to compounds that bind to Lysophosphatidic Acid Receptor 1 (LPAR1) and act as antagonists of LPAR1. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of LPAR1, including fibrosis and liver diseases such as non-alcoholic steatohepatitis (NASH), interstitial lung disease (ILD), or chronic kidney disease (CKD).
    Type: Grant
    Filed: May 13, 2021
    Date of Patent: February 21, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Brian P. Bestvater, Zhimin Du, Julie Farand, Joshua A. Kaplan, Barton W. Phillips, Doris T. Tang, Chandrasekar Venkataramani, Peiyuan Wang, Kin S. Yang, Anna Zagorska
  • LPA RECEPTOR ANTAGONISTS AND USES THEREOF
    Publication number: 20230012262
    Abstract: The present disclosure relates generally to compounds that bind to Lysophosphatidic Acid Receptor 1 (LPAR1) and act as antagonists of LPAR1. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of LPAR1, including fibrosis and liver diseases such as non-alcoholic steatohepatitis (NASH), interstitial lung disease (ILD), or chronic kidney disease (CKD).
    Type: Application
    Filed: May 13, 2021
    Publication date: January 12, 2023
    Inventors: Brian P. Bestvater, Zhimin Du, Julie Farand, Joshua A. Kaplan, Barton W. Phillips, Doris T. Tang, Chandrasekar Venkataramani, Peiyuan Wang, Kin S. Yang, Anna Zagorska
  • LPA RECEPTOR ANTAGONISTS AND USES THEREOF
    Publication number: 20220411405
    Abstract: The present disclosure relates generally to compounds that bind to Lysophosphatidic Acid Receptor 1 (LPAR1) and act as antagonists of LPAR1. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of LPAR1, including fibrosis and liver diseases such as non-alcoholic steatohepatitis (NASH), interstitial lung disease (TLD), or chronic kidney disease (CKD).
    Type: Application
    Filed: May 10, 2022
    Publication date: December 29, 2022
    Inventors: Brian P. Bestvater, Joshua A. Kaplan, Megan E. Neubig, Kin S. Yang, Anna Zagorska
  • FXR (NR1H4) MODULATING COMPOUNDS
    Publication number: 20220204491
    Abstract: The present disclosure relates generally to compounds that bind to FXR and act as agonists of FXR. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.
    Type: Application
    Filed: November 24, 2021
    Publication date: June 30, 2022
    Inventors: Peter A. Blomgren, Kevin S. Currie, Morin Mae Frick, Elizabeth M. Horstman, Joshua A. Kaplan, Jeffrey E. Kropf, William J. Watkins
  • SULFINYLAMINOBENZAMIDE AND SULFONYLAMINOBENZAMIDE DERIVATIVES
    Publication number: 20220055985
    Abstract: Provided is a compound of Formula (I): wherein the variable groups are defined herein.
    Type: Application
    Filed: August 31, 2021
    Publication date: February 24, 2022
    Inventors: Julie FARAND, Joshua A. KAPLAN, Gregory NOTTE, Casey Lockwood OLEN, Michael SANGI, David SPERANDIO
  • FXR (NR1H4) modulating compounds
    Patent number: 11225473
    Abstract: The present disclosure relates generally to compounds that bind to FXR and act as agonists of FXR. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.
    Type: Grant
    Filed: January 13, 2020
    Date of Patent: January 18, 2022
    Assignee: Gilead Sciences, Inc.
    Inventors: Peter A. Blomgren, Kevin S. Currie, Morin Mae Frick, Elizabeth M. Horstman, Joshua A. Kaplan, Jeffrey E. Kropf, William J. Watkins
  • Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives
    Patent number: 11136290
    Abstract: Provided is a compound of Formula (I): wherein the variable groups are defined herein.
    Type: Grant
    Filed: May 17, 2019
    Date of Patent: October 5, 2021
    Assignee: The Liver Company Inc.
    Inventors: Julie Farand, Joshua A. Kaplan, Gregory Notte, Casey Lockwood Olen, Michael Sangi, David Sperandio
  • SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF
    Publication number: 20210251957
    Abstract: This application relates generally to certain substituted pyrrolizine compounds, and pharmaceutical compositions which inhibit HBV replication, and methods of making and using them.
    Type: Application
    Filed: November 4, 2020
    Publication date: August 19, 2021
    Inventors: Jinfa DU, Joshua A. KAPLAN, Thorsten A. KIRSCHBERG, Tetsuya KOBAYASHI, Scott E. LAZERWITH, Rick Andrew LEE, Jonathan William MEDLEY, Michael L. MITCHELL, Philip Anthony MORGANELLI, Hyung-Jung PYUN, Sophia L. SHEVICK, Neil H. SQUIRES, William J. WATKINS
  • Substituted pyrrolizine compounds and uses thereof
    Patent number: 10874640
    Abstract: This application relates generally to certain substituted pyrrolizine compounds, and pharmaceutical compositions which inhibit HBV replication, and methods of making and using them.
    Type: Grant
    Filed: May 3, 2019
    Date of Patent: December 29, 2020
    Assignee: GILEAD SCIENCES, INC.
    Inventors: Jinfa Du, Joshua A. Kaplan, Thorsten A. Kirschberg, Tetsuya Kobayashi, Scott E. Lazerwith, Rick Andrew Lee, Jonathan William Medley, Michael L. Mitchell, Philip Anthony Morganelli, Hyung-Jung Pyun, Sophia L. Shevick, Neil H. Squires, William J. Watkins
  • FXR (NR1H4) MODULATING COMPOUNDS
    Publication number: 20200255418
    Abstract: The present disclosure relates generally to compounds that bind to FXR and act as agonists of FXR. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.
    Type: Application
    Filed: January 13, 2020
    Publication date: August 13, 2020
    Inventors: Peter A. Blomgren, Kevin S. Currie, Morin Mae Frick, Elizabeth M. Horstman, Joshua A. Kaplan, Jeffrey E. Kropf, William J. Watkins